Neil J - Search Results

1

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Bahlis NJ, et al. Among authors: neil j. Clin Cancer Res. 2002 Dec;8(12):3658-68. Clin Cancer Res. 2002. PMID: 12473574 Clinical Trial.

2

Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts.

Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC. Kilbey A, et al. Cancer Res. 2007 Dec 1;67(23):11263-71. doi: 10.1158/0008-5472.CAN-07-3016. Cancer Res. 2007. PMID: 18056452 Free PMC article.

3

Runx2 in normal tissues and cancer cells: A developing story.

Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, Stein T, Neil J, Cameron ER. Blyth K, et al. Among authors: neil j. Blood Cells Mol Dis. 2010 Aug 15;45(2):117-23. doi: 10.1016/j.bcmd.2010.05.007. Epub 2010 Jun 26. Blood Cells Mol Dis. 2010. PMID: 20580290

4

Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.

Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, Neil JC, Cameron ER. Wotton S, et al. Cancer Res. 2002 Dec 15;62(24):7181-5. Cancer Res. 2002. PMID: 12499254

5

The Runx genes as dominant oncogenes.

Cameron ER, Blyth K, Hanlon L, Kilbey A, Mackay N, Stewart M, Terry A, Vaillant F, Wotton S, Neil JC. Cameron ER, et al. Blood Cells Mol Dis. 2003 Mar-Apr;30(2):194-200. doi: 10.1016/s1079-9796(03)00031-7. Blood Cells Mol Dis. 2003. PMID: 12732183 Review.

6

RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53.

Wotton SF, Blyth K, Kilbey A, Jenkins A, Terry A, Bernardin-Fried F, Friedman AD, Baxter EW, Neil JC, Cameron ER. Wotton SF, et al. Oncogene. 2004 Jul 15;23(32):5476-86. doi: 10.1038/sj.onc.1207729. Oncogene. 2004. PMID: 15133495

7

The Runx genes: lineage-specific oncogenes and tumor suppressors.

Cameron ER, Neil JC. Cameron ER, et al. Oncogene. 2004 May 24;23(24):4308-14. doi: 10.1038/sj.onc.1207130. Oncogene. 2004. PMID: 15156187 Review.

8

The RUNX genes: gain or loss of function in cancer.

Blyth K, Cameron ER, Neil JC. Blyth K, et al. Nat Rev Cancer. 2005 May;5(5):376-87. doi: 10.1038/nrc1607. Nat Rev Cancer. 2005. PMID: 15864279 Review.

9

Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.

Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. Blyth K, et al. Cancer Res. 2006 Feb 15;66(4):2195-201. doi: 10.1158/0008-5472.CAN-05-3558. Cancer Res. 2006. PMID: 16489021

10

Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas.

Stewart M, Mackay N, Hanlon L, Blyth K, Scobie L, Cameron E, Neil JC. Stewart M, et al. Cancer Res. 2007 Jun 1;67(11):5126-33. doi: 10.1158/0008-5472.CAN-07-0433. Cancer Res. 2007. PMID: 17545590 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

614 results

Search Page